The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study - 10/09/17
, Rieke Alten b, Hubert G. Nüßlein c, Mauro Galeazzi d, Hanns-Martin Lorenz e, Alain Cantagrel f, Melanie Chartier g, Coralie Poncet h, 1, Christiane Rauch i, Manuela Le Bars jBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 3 |
| Video | 0 |
| Altro | 0 |
Abstract |
Objective |
To assess the impact of baseline body mass index (BMI) on the efficacy and retention of intravenous abatacept at 6 months in biologic-naïve patients with rheumatoid arthritis (RA).
Methods |
This was a 6-month analysis of a 2-year, non-interventional, international, prospective study. Baseline characteristics, clinical response and retention rates were compared by BMI subgroup: underweight/normal, overweight and obese (<25, 25 to <30 and ≥30kg/m2, respectively).
Results |
BMI was reported in 643/672 (96%) patients: 264 (41%) were underweight/normal, 224 (35%) overweight and 155 (24%) obese. At baseline, the obese group had more active disease (mean [95% confidence intervals] 28-joint Disease Activity Score [C-reactive protein; derived] 4.6 [4.5, 4.7], 4.8 [4.7, 5.0] and 5.1 [4.9, 5.2] for underweight/normal, overweight and obese groups, respectively), a higher prevalence of metabolic disorders, a greater proportion of women and a lower proportion of patients with rheumatoid factor positivity. There were no significant differences in the percentages of patients achieving a good/moderate European League Against Rheumatism response by BMI group (80.7, 86.1 and 77.0% for underweight/normal, overweight and obese groups, respectively; P=0.178). Overall retention rates at 6 months did not differ across groups (89, 92 and 89% for underweight/normal, overweight and obese groups, respectively; log-rank P=0.382). After adjustment for baseline characteristics, BMI was not significantly associated with risk of discontinuation (reference BMI<25kg/m2; hazard ratio [95% confidence intervals] 0.46 [0.22, 0.99] and 0.69 [0.34, 1.41] for overweight and obese patients, respectively).
Conclusion |
BMI does not impact abatacept clinical response or retention in biologic-naïve patients with RA.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Abatacept, Body mass index, EULAR response, Real-world study, Retention rate, Rheumatoid arthritis
Mappa
Vol 84 - N° 5
P. 571-576 - Ottobre 2017 Ritorno al numero
Articolo precedente
- Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials
- Arnaud Mazouyès, Marine Clay, Anne-Catherine Bernard, Philippe Gaudin, Athan Baillet
- Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial
- Agnès Portier, Laure Gossec, Florence Tubach, Toni Alfaiate, Thao Pham, Alain Saraux, Martin Soubrier, Thierry Schaeverbeke, Jean-Francis Maillefert, Xavier Mariette, David Hajage, Bruno Fautrel
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?